Patents Assigned to Boehringer Ingelheim Pharmaceuticals, Inc.
  • Method and system for assisted culling and reformatting of encoded microtubes
    Patent number: 7222792
    Abstract: A method and system for aiding the selecting/culling or reformatting of encoded containers stored in a multi-rack array with respect to certain desired characteristics of compositions held within the containers employing a corresponding graphical interface that indicates the physical position of the containers within the array, and selection operations to be performed with respect to one or more containers in the array.
    Type: Grant
    Filed: November 8, 2005
    Date of Patent: May 29, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michael Stanley Routburg, Kenneth Hendrata
  • Anti-cytokine heterocyclic compounds
    Patent number: 7214802
    Abstract: Disclosed compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: May 8, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Derek Cogan, Ming-Hong Hao, Victor Marc Kamhi, Craig Andrew Miller, Matthew Russell Netherton, Alan David Swinamer
  • Method for Improving the Ability of Patients Suffering from Lung Diseases to Participate In and Benefit from Pulmonary Rehabilitation Programs
    Publication number: 20070099949
    Abstract: A method for improving the ability of a patient suffering from a lung disease to participate in and benefit from a pulmonary rehabilitation program, the method comprising administering to the patient a therapeutically effective amount of a tiotropium salt.
    Type: Application
    Filed: August 31, 2006
    Publication date: May 3, 2007
    Applicants: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Bernd Disse, Steven Kesten, Theodore Witek
  • Methods of treating cytokine mediated diseases
    Patent number: 7211575
    Abstract: Disclosed are methods of treating acute and chronic inflammation in the lung caused by inhalation of smoke, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, sepsis, chronic obstructive pulmonary disease, traumatic arthritis, congestive heart failure and restenosis following percutaneous transluminal coronary angioplasty, known to be cytokine mediated, using aromatic heterocyclic compounds described in WO 00/55139.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: May 1, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Neil Moss, John Robinson Regan
  • Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Publication number: 20070060633
    Abstract: Compounds of Formula (IA) and (IB) wherein R1, R2, R3, A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Application
    Filed: June 8, 2006
    Publication date: March 15, 2007
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Ingo Mugge, David Thomson, Abdelhakim Hammach, Michael Burke, Mark Ralph, Jennifer Kowalski, Joerg Bentzien
  • Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
    Patent number: 7189758
    Abstract: A compound of Formula (I) wherein R1, R2, R3, R4, R5, and R6 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: March 13, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Rajashekhar Betageri, David Thomson, Yan Zhang, Renee Michele Zindell
  • Dipeptide synthesis
    Patent number: 7186827
    Abstract: Disclosed are processes of making dipeptide compounds of formula(I) as further described in the detailed description section:
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: March 6, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Carl Alan Busacca, Nizar Haddad, Suresh R. Kapadia, Lana Smith Keenan, Jon Charles Lorenz, Chris Hugh Senanayake, Xudong Wei
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Patent number: 7186864
    Abstract: A compound of Formula (IA) or Formula (IB) wherein R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: March 6, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Thomas Martin Kirrane, Jr., Daniel Kuzmich, John Robert Proudfoot, David Thomson
  • Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
    Patent number: 7179919
    Abstract: A process for stereoselective synthesis of a compound of Formula (I) wherein R1, R2, R3, R4, and R5 are as described herein.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: February 20, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Jinhua J. Song, Zhulin Tan, Nathan K. Yee, Chris Hugh Senanayake, Jinghua Xu, Fabrice Gallou
  • Crystal structure of the ITK kinase domain
    Publication number: 20070032403
    Abstract: Disclosed are polypeptides encoding the ITK kinase domain and nucleic acids encoding such polypeptides, crystal structures of various polypeptide-ligand complexes comprising the ITK kinase domain bound to a ligand, methods of producing the aforementioned polypeptides and nucleic acids which encode them and methods of producing crystal structures of the aforementioned polypeptides comprising the ITK kinase domain bound to a ligand.
    Type: Application
    Filed: December 23, 2004
    Publication date: February 8, 2007
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Joerg Bentzien, Bennett Farmer, Steven Pullen, Joey Studts, Andre White
  • Cytokine Inhibitors
    Publication number: 20070032492
    Abstract: Disclosed are compounds of formula (I) Where Ar1, X, R3, R4, R5 and R6 are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: September 7, 2006
    Publication date: February 8, 2007
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Derek Cogan, Ming-Hong Hao, Kevin Qian, Alan Swinamer
  • Pyrimidine derivatives
    Patent number: 7173028
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: February 6, 2007
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Cytokine inhibitors
    Patent number: 7166628
    Abstract: Disclosed are compounds of formula (I) Where Ar1, X, R3, R4, R5 and R6 are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: January 23, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Derek A. Cogan, Ming-Hong Hao, Kevin Chungeng Qian, Alan David Swinamer
  • Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines
    Publication number: 20070009498
    Abstract: Unique multifunctional nucleotide expression cassettes comprising a nucleotide sequence encoding a human protease driven by a glucose-regulatable promoter, a nucleotide sequence encoding human proinsulin having sites at its B-C and C-A junctions altered to permit cleavage by the human protease, and a CMV promoter driving the transcription of the nucleotide sequence encoding the human proinsulin, such cassettes optionally having polyadenylation sequences after each structural gene and the nucleotide sequence encoding human proinsulin optionally carrying an H10D variant, and cells transformed thereby.
    Type: Application
    Filed: January 17, 2006
    Publication date: January 11, 2007
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Revati Tatake, Richard Schneiderman, Randall Barton
  • Anti-Cytokine Heterocyclic Compounds
    Publication number: 20060276453
    Abstract: Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.
    Type: Application
    Filed: March 17, 2006
    Publication date: December 7, 2006
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Daniel Goldberg, Asitha Abeywardane, Craig Miller, Tina Morwick, Matthew Netherton, Roger Snow, Ji Wang, Jiang-Ping Wu, Zhaoming Xiong
  • Anti-Cytokine Heterocyclic Compounds
    Publication number: 20060276496
    Abstract: Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.
    Type: Application
    Filed: March 17, 2006
    Publication date: December 7, 2006
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Daniel Goldberg, Asitha Abeywardane, Craig Miller, Tina Morwick, Matthew Netherton, Roger Snow, Ji Wang, Jiang-Ping Wu, Zhaoming Xiong
  • Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
    Publication number: 20060270671
    Abstract: Disclosed are methods of treating cancer by administration of compounds according to formula (I): wherein the variables R1, R2, R3 and Z are described herein.
    Type: Application
    Filed: August 7, 2006
    Publication date: November 30, 2006
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Zhidong Chen, Pier Cirillo, Darren DiSalvo, Weimin Liu, Daniel Marshall, Lifen Wu, Erick Young
  • T cell protein and nucleotides encoding the same
    Publication number: 20060269991
    Abstract: The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma.
    Type: Application
    Filed: October 31, 2005
    Publication date: November 30, 2006
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Jianfei Yang, Frank King, Jun Li, Zhen Qi, Ming Xue
  • Fluorescent probes for use in protein kinase inhibitor binding assay
    Publication number: 20060263841
    Abstract: The invention provides methods relating to a novel screening assay format that can be applied to broad members of the protein kinase gene family. The assay uses a series of labeled, active site probes described herein that can be displaced by an inhibitor agent. The Kd for the inhibitor compound is derived based on the Kd of the probe for the kinase and the dose response of the inhibitor agent. The invention also provides novel active site probes suitable for use with the screening method.
    Type: Application
    Filed: July 25, 2006
    Publication date: November 23, 2006
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Anthony Prokopowicz, Martha Brown, Jessi Wildeson, Scott Jakes, Mark Labadia
  • Substituted benzimidazole compounds
    Patent number: 7138420
    Abstract: Disclosed are substituted benzimidazole compounds of formula (I): wherein R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: November 21, 2006
    Assignee: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Joerg Martin Bentzien, Brian Nicholas Cook, Charles Cywin, Roman Wolfgang Fleck, Ho Yin Lo, Peter Allen Nemoto, Steven S. Pullen, Gregory Paul Roth, Roger John Snow, Hidenori Takahashi, Ji Wang, Kevin J. Moriarty, Lei Qiao, Michael Winters